NCT07563881Phase 3Recruiting

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Study sponsor: Rapport Therapeutics Inc. · RAPP

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-07Estimated
Enrollment · participants333Estimated
Source updated2026-11-16Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source